In Brief
The Alzheimer's disease risk factor TREM2 regulates microglial function through modulation of cellular biosynthetic metabolism.
INTRODUCTION
Alzheimer's disease (AD) is the most common cause of lateonset dementia. AD lesions in the CNS include plaques of amyloid b (Ab) peptides and neurofibrillary tangles of hyperphosphorylated tau protein, both linked to synapse loss, neuronal death, and ultimately cognitive decline (Holtzman et al., 2011; Huang and Mucke, 2012) . Rare familial AD is due to mutations in amyloid precursor protein (APP) and presenilins (PS) that promote the generation of Ab peptides prone to aggregation (Tanzi, 2012) . However, the risk for common late-onset AD is associated with rare variants of immune receptors expressed on microglia (Guerreiro and Hardy, 2014; Tanzi, 2012) . One of these receptors, TREM2, recognizes phospholipids, apoptotic cells, and lipoproteins (Atagi et al., 2015; Bailey et al., 2015; Wang et al., 2015; Yeh et al., 2016) . TREM2 transmits intracellular signals through two adapters, DAP12 and DAP10, which recruit protein tyrosine kinase Syk and phosphatidylinositol 3-kinase (PI3-K), respectively (Peng et al., 2010) . Arginine-to-histidine variants at position 47 (R47H) or 62 (R62H) of TREM2 increase the risk for sporadic AD and impair binding to phospholipid ligands (Atagi et al., 2015; Bailey et al., 2015; Guerreiro and Hardy, 2014; Wang et al., 2015; Yeh et al., 2016) . These variants, as well as TREM2 deficiency and haploinsufficiency in mouse models of AD, moderate microglial proliferation, survival, and accumulation around Ab plaques, thereby facilitating Ab plaque buildup and injury of adjacent neurons (Jay et al., 2017; Ulrich et al., 2014; Wang et al., 2015 Wang et al., , 2016 Yuan et al., 2016) . TREM2 has also been implicated in microglial phagocytosis of dead neurons, damaged myelin, and Ab plaques (Neumann and Takahashi, 2007; Yeh et al., 2016) . However, why defective TREM2 function or expression affects microglia responses to AD lesions is not known.
To address this question, we first used electron and confocal microscopy to analyze microglia from 5XFAD mice, which develop Ab accumulation that mimics AD pathology due to the expression of mutant APP and PS1 under neural-specific elements of the mouse Thy1 promoter. Microglia from 5XFAD mice lacking TREM2 had many more autophagic vesicles than did microglia in 5XFAD mice. This observation was replicated in humans, as microglia in AD patients carrying TREM2 risk variants also had more autophagic vesicles than did microglia in AD patients with the common TREM2 variant. Autophagy is 
(legend continued on next page)
an intracellular degradation pathway essential for cellular and energy homeostasis (Galluzzi et al., 2014) . It provides a mechanism for the elimination of misfolded proteins and damaged organelles and compensates for nutrient deprivation during cell starvation through recycling of cytosolic components. Because autophagy is partially regulated by mammalian target of rapamycin (mTOR)-dependent pathways (Saxton and Sabatini, 2017) , we assessed the impact of TREM2-deficiency on mTOR activation and found that, indeed, anomalous autophagy reflected defective activation of mTOR signaling. Similarly, enhanced autophagy was observed in TREM2-deficient macrophages in vitro, which was further amplified by growth-factor limitation or endoplasmic reticulum (ER) stress; this provided a model system for probing biochemical and metabolic pathways in microglia during Ab accumulation. Combined metabolomics, RNA sequencing (RNA-seq), and system analyses of TREM2-deficient macrophages confirmed the impairment of mTOR activation, energetic pathways, ATP levels, and biosynthetic pathways. Thus, TREM2 sustains cell energetic and biosynthetic metabolism through mTOR signaling. Metabolic derailment and autophagy were offset in vitro through activation of Dectin-1, a surface receptor that triggers a signaling pathway similar to that of TREM2-DAP12 (Dambuza and Brown, 2015) . Metabolic abnormalities were also rescued by incubating cells with the creatine analog 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine), which can passively cross membranes and, upon phosphorylation by creatine kinase, generate a supply of ATP for energy demands independent of the TREM2-mTOR axis . Remarkably, dietary administration of cyclocreatine in 5XFAD mice lacking TREM2 prevented microglial autophagy, enhanced microglia numbers and clustering around Ab plaques, and mitigated plaque-associated neurite dystrophy. This provides proof of principle that strategies aimed at sustaining basic microglial metabolism may be promising for treatment of AD and other neurodegenerative diseases associated with microglial dysfunction.
RESULTS

Defect in TREM2 Elicits Autophagy In Vivo in the 5XFAD Mouse Model and AD Patients
To determine the impact of TREM2 deficiency on microglia function, we examined the structure of microglia from the 5XFAD mouse model of AD by transmission electron microscopy (TEM). Strikingly, microglia from Trem2 -/-5XFAD mice contained abundant multivesicular/multilamellar structures suggestive of autophagosomes, which were largely absent in microglia from 5XFAD, Trem2 -/-, or wild-type (WT) mice (Figures 1A and 1B) . To determine whether these structures reflected ongoing autophagy in situ, we examined brain sections by confocal microscopy for the presence of LC3 + puncta, which denote autophagosomes decorated by lipidated LC3II (Klionsky et al., 2016) . Many large LC3 + puncta were evident in microglia in
Trem2
-/-5XFAD mice, whereas LC3 + puncta were sparse in microglia in WT, Trem2
, and 5XFAD mice ( Figures 1C, 1D , and S1). These observations were translatable to human disease. We observed dramatically more LC3 + microglia in postmortem brain sections from both R47H and R62H heterozygous AD patients than in those from case-matched AD patients homozygous for the common TREM2 variant (Figures 1E and  1F ; Table S1 ). Taken together, these data suggest that autophagic-like vesicles accumulate in the microglia of TREM2-deficient mice and humans with TREM2 risk alleles during the development of AD.
TREM2 Deficiency Impairs mTOR Signaling and Enhances AMPK Activation in Microglia
To corroborate the association between TREM2 deficiency and increased autophagy, we performed biochemical analyses on sorted microglia ex vivo. The ratio of lipidated LC3II to non-lipidated LC3I was markedly higher in microglia from Trem2 -/-5XFAD mice than in microglia from 5XFAD mice, consistent with the increased number of autophagic vesicles in TREM2-deficient microglia (Figures 2A and 2B ). To determine whether the increase in autophagosomes was due to activation of autophagy or blockade of lysosomal degradation, we measured protein and mRNA levels of p62, an autophagy cargo protein that is digested by lysosomal enzymes. The amount of p62 protein was lower in microglia from Trem2 -/-5XFAD mice than in microglia from 5XFAD mice. This difference was unrelated to transcription, as p62 (Sqstm1) mRNA levels were similar (Figures 2A and S2A ). Thus, TREM2 deficiency results in bona fide autophagy. Why is autophagic flux amplified in 5XFAD mice lacking TREM2? Autophagy often reflects an adaptive response to stress that can occur when cells cannot satisfy increased demands for energy and protein synthesis (Kroemer et al., 2010) . Because the serine/threonine kinase target of rapamycin (mTOR) has a crucial role in stimulating both energetic and anabolic metabolism, cell growth, and proliferation (Laplante and Sabatini, 2012) , we hypothesized that the autophagy observed in microglia in Trem2 -/-5XFAD mice might result from a defect in mTOR signaling. mTOR signals through two distinct complexes, mTORC1 and mTORC2. Immunoblotting of sorted microglia from Trem2 -/-5XFAD and 5XFAD mice revealed See also Figure S1 and Table S1 .
decreased phosphorylation of 4EBP1, an mTORC1 effector, as well as Akt (serine 473) and NDRG1, both mTORC2 effectors, in the TREM2-deficient microglia ( Figure 2A ). Ulk1, a key inducer of autophagy, which is inhibited by mTOR signaling through phosphorylation at serine 757 (Kim et al., 2011) , was less phosphorylated in microglia from Trem2 -/-5XFAD mice, consistent with reduced mTOR activation and increased autophagy (Figure 2A) . Impaired mTOR signaling was associated with phosphorylation of AMP-activated protein kinase (AMPK), a sensor of low energy states ( Figure 2A ). Providing further evidence for defective energetic and anabolic metabolism associated with TREM2 deficiency, , 5XFAD, and Trem2 -/-5XFAD mice were taken as in Figure 1C . Images depict Iba-1 + microglia (red), methoxy X04 + plaques (blue), and cleaved caspase-3 (green).
(F) Quantification of the % of LC3 + microglia that are positive for cleaved caspase-3.
Error bar represents mean ± SEM. ****p < 0.001 by one-way ANOVA with Holm-Sidak's multiple comparisons test (B and F). **p < 0.01 by Student's t test (D).
Immunoblots are representative of 3 independent experiments from microglia from 3 separate mice per group (A). Confocal images are representative of 3 female mice per group (E). See also Figure S2 .
microglia from Trem2 -/-5XFAD mice had a lower mitochondrial mass than microglia from 5XFAD mice ( Figures 2C and 2D) . Furthermore, gene expression microarray analyses of sorted microglia from Trem2 -/-5XFAD and 5XFAD mice revealed that TREM2 deficiency was associated with decreased expression of genes encoding translation initiation factors, ribosomal proteins, glucose transporters, glycolytic enzymes, as well as the transcription factor HIF1a that controls glycolysis ( Figures  S2B-S2G ). Taken together, these data demonstrate that during the development of AD, TREM2 deficiency derails the mTOR pathway, anabolic and energetic metabolism in microglia, which induces compensatory autophagy in both mice and humans.
To determine whether autophagy in TREM2-deficient microglia can effectively compensate for the metabolic defects in vivo and prevent apoptosis, we examined brain sections by confocal microscopy for the presence of cleaved caspase-3, an indicator of apoptosis. We found that cleaved caspase-3 was much more abundant in microglia in Trem2 -/-5XFAD mice than in microglia in 5XFAD mice (Figures 2E and 2F) . Additionally, the percentage of microglia with colocalization of cleaved caspase-3 and LC3 + puncta was higher in Trem2 -/-5XFAD mice than in 5XFAD mice ( Figures S2H and S2I ). Thus, autophagy may not be sufficient to sustain the microglial response to stress, at least at the late time point of disease progression analyzed.
Macrophages Lacking TREM2 Inadequately Signal through mTOR and Undergo More Autophagy
We then asked whether TREM2-deficiency could derail mTOR signaling in bone marrow-derived macrophages (BMDMs) in vitro. To mimic the metabolic stress that occurs during disease, we used growth-factor deprivation. BMDMs were cultured overnight in concentrations of CSF1-containing L cell-conditioned medium (LCCM) ranging from optimal to limiting (10% to 0.5%). Trem2 -/-BMDMs contained more autophagic vesicles (Figures 3A and 3B) and had a higher LC3II/LC3I ratio than WT cells when CSF1 was limiting ( Figure 3C ). Addition of the lysosomal inhibitor bafilomycin greatly increased LC3II in Trem2 -/-BMDMs, confirming that the increase in autophagosomes was due to increased autophagic flux rather than reduced autophagosome degradation ( Figures 3D and 3E ). As observed in sorted microglia, autophagy in BMDMs was linked to impaired mTOR signaling. Trem2 -/-BMDMs had less phosphorylated 4EBP1, Akt (serine 473), and NDRG1 ( Figure 3F ) and more phosphorylated AMPK ( Figure 3G ) in both optimal CSF1 and limiting CSF1 than did WT BMDMs. In limiting CSF1, Trem2 -/-BMDMs had decreased inhibitory phosphorylation of Ulk1 at serine 757, while activating phosphorylation of Ulk1 at serine 317 increased ( Figure 3H ). Thus, lack of TREM2 suppressed mTOR activation and elicited compensatory AMPK and Ulk1 activation and autophagy in BMDMs in response to metabolic stress, very similar to our observations of microglia in 5XFAD mice.
As TREM2 signaling adapters DAP12 and DAP10 have been shown to activate PI3-K, which in turn can activate mTOR, we asked whether enhanced mTOR signaling in WT BMDM compared to Trem2 -/-BMDM was dependent on PI3-K. TREM2 signaling may not just have a more pronounced effect on cells under stress conditions, but may actually increase under such conditions. When cultured in media containing 10% fetal bovine serum (FBS), TREM2 reporter cells, which express GFP upon TREM2 engagement (Wang et al., 2015) , showed some activation ( Figure S3B ). However, upon serum starvation, a significantly higher proportion of reporter cells became activated, possibly due to exposure of the TREM2 ligand phosphatidylserine on the outer leaflet of stressed cells. This activation could be blocked by inclusion of an anti-TREM2 antibody. Thus, in multiple in vitro settings of stress, TREM2-expressing cells are more able to sustain mTOR activation and suppress autophagy in a PI3-K-dependent manner than are cells lacking TREM2.
TREM2 Deficiency Curtails Anabolic and Energetic Metabolism in BMDMs
To directly demonstrate the impact of TREM2 deficiency on energetic and anabolic pathways in BMDMs, we performed mass spectrometry to quantify cellular metabolites and RNAseq to quantify mRNA levels of metabolic enzymes. Analysis of metabolite data alone, or in combination with RNA-seq data by a systems-based algorithm (Sergushichev et al., 2016) , revealed widespread differences between WT and Trem2 -/-BMDMs in various metabolic pathways. Compared to WT BMDMs in optimal CSF1, Trem2 -/-BMDMs cultured under the same conditions exhibited (1) a marked decrease of key intermediates in the synthesis of nucleotides (e.g., phosphoribosyl pyrophosphate), N-glycosylated proteins (e.g., UDP-glucose), and phospholipids (e.g., CDP-ethanolamine); (2) a decrease in glycolytic metabolites (e.g., glucose 6-phosphate and fructose bisphosphate) and tricarboxylic acid (TCA) cycle intermediates (citrate and succinate); and (3) an increase in catabolic products of amino acids (e.g., indolacetate) and phospholipids (e.g., glycerol 3-phosphate) ( Figures 4A and S4A ). Moreover, a selective increase in malate and fumarate suggested an enhanced malate-aspartate shuttle to sustain defective NADH oxidation and NAD regeneration ( Figure 4A ). Unbiased network analysis combining metabolic and RNA-seq data highlighted defects in metabolites and enzymes involved in glycolysis, TCA cycle, and pentose phosphate pathway in Trem2 -/-BMDMs ( Figure 4B ).
CSF1 reduction further deteriorated energy and anabolic metabolism in Trem2
-/-BMDMs. Under these conditions, again in comparison to WT BMDMs, Trem2 -/-BMDMs underwent a marked increase in symmetrical dimethyl arginine, indicative of protein catabolism, as well as an increase in ADP-ribose, indicative of NAD degradation ( Figures 4C, S4B , and S4C). Furthermore, stores of high-energy phosphates, such as phosphocreatine and ATP, were depleted in Trem2 -/-BMDMs cultured in limiting CSF1 conditions ( Figure S4D ). A luciferasebased ATP assay confirmed an ATP deficiency in Trem2 -/-BMDMs, which was exacerbated at low CSF1 concentrations ( Figure 4D ). We further assessed the energy metabolism of WT and Trem2 -/-BMDMs using the Seahorse analyzer. A lower extracellular acidification rate (ECAR), indicative of less glycolytic flux, was noted in Trem2 -/-BMDMs both at baseline and after induction of maximal glycolytic capacity by oligomycin and fluoro-carbonyl cyanide phenylhydrazone (FCCP). This deficit widened relative to WT cells as the CSF1 concentration was reduced ( Figure 4E ). Trem2 -/-BMDMs had only a slightly reduced oxygen consumption rate (OCR) compared to WT BMDMs when cultured in standard CSF1 concentrations, indicating relatively intact oxidative phosphorylation; however, a deficit in OCR emerged as the CSF1 concentration was reduced ( Figure 4E ). Trem2 -/-BMDMs also had fewer mitochondria than WT BMDMs on a per cell basis as measured by MitoTracker Green fluorescence and by the mitochondrial-to-nuclear DNA ratio ( Figures 4F and 4G ). These findings were not restricted to BMDMs, as resting and thioglycolate-elicited peritoneal TREM2-deficient macrophages also had a lower mitochondrial mass than did WT macrophages ( Figures S4E-S4H ). Cultured adult primary Trem2 -/-microglia recapitulated the deficiencies in energetic metabolism and mTOR signaling as well as autophagy observed in Trem2 -/-BMDMs ( Figures S4I-S4M ). Thus, lack of TREM2-mTOR signaling impairs the energy status and anabolism of BMDMs and other primary macrophages both in steady state and under energetic stress.
Enhanced Energy Storage or Dectin-1 Signaling Can Compensate for TREM2 Deficiency In Vitro Given the dramatic effect of TREM2 deficiency on mTOR activation and energy utilization in BMDMs, we tested whether bypassing TREM2 and directly compensating for these deficits by alternative means could restore the cellular energy status of Trem2 -/-BMDMs. Muscle physiology studies have extensively demonstrated that creatine phosphate contributes to the regeneration of ATP and to the maintenance of uniformly high ATP/ ADP ratios in muscle fibers (Walker, 1979) . Moreover, the creatine analog 1-carboxymethyl-2-iminoimidazolidine (cyclocreatine) can, upon phosphorylation, generate a long-acting phosphagen that can effectively sustain cellular ATP levels during increased energy demand Woznicki and Walker, 1979 ). Thus, we tested whether addition of cyclocreatine to the culture medium could rescue energetic metabolism in Trem2-deficient BMDMs. Indeed, incubation with cyclocreatine improved ECAR, which was accompanied by less autophagy, increased mTOR signaling and cell viability (Figures 5A-5C and data not shown).
To test whether engagement of receptors that elicit signaling pathways similar to those of TREM2 could also mitigate autophagy and support cell survival, Trem2
-/-and WT BMDMs were cultured with depleted zymosan, a selective ligand of Dectin-1, which activates Syk and PI3-K signaling independent of DAP12 (Dambuza and Brown, 2015) . Dectin-1 activation curbed autophagy in CSF1-starved TREM2-deficient BMDMs to levels seen in WT BMDMs in low CSF1, as indicated by a reduction in the LC3II/LC3I ratio ( Figures 5D and 5E ) along with increased amounts of p62 ( Figure 5F ). Treatment with zymosan also enhanced cellular ATP levels in Trem2 -/-BMDMs, restoring them to WT BMDM levels ( Figure 5G ). Thus, alternative energetic and signaling pathways can compensate for lack of TREM2 signaling.
Cyclocreatine Figure 6E ), although other parameters did not reach statistical significance ( Figures S5B-S5D ). Furthermore, clustering of microglia around plaques ( Figures 6C and 6F ) and the number of microglia/HPF in plaque-bearing regions of the cortex ( Figure S5E ) were both significantly increased in Trem2 -/-5XFAD mice treated with cyclocreatine compared to untreated Trem2 -/-5XFAD mice. These findings indicate that dietary supplementation with cyclocreatine is sufficient to partially rescue the defect in microgliosis and microglial clustering around plaques in Trem2 -/-5XFAD mice, while concomitantly mitigating autophagy and death of the microglia.
To assess the impact of cyclocreatine on microglial activation, which is also impaired in Trem2 -/-5XFAD mice, we quantified the percentage of microglia that expressed the activation marker osteopontin (Spp1), a protein that, in the brain, is upregulated in microglia in the context of Ab deposition (Orre et al., 2014; Wang et al., 2015) . Untreated Trem2 -/-5XFAD mice had very few Spp1 + microglia, while cyclocreatine-treated Trem2 -/-5XFAD mice had significantly more Spp1 + microglia, as did TREM2-sufficient 5XFAD mice ( Figures 7A and 7B) . Moreover, biochemical analysis of microglia isolated ex vivo demonstrated that cyclocreatine treatment of Trem2 -/-5XFAD mice also restored microglial mTOR signaling and limited autophagy compared to untreated Trem2 -/-5XFAD mice ( Figures 7C and 7D) .
As a major function of TREM2 in vivo is enabling microglia to form a barrier around plaques that prevents spreading of Ab fibrils and alleviates dystrophy of plaque-adjacent neurites (Wang et al., 2016; Yuan et al., 2016) , we asked whether cyclocreatine treatment of Trem2 -/-5XFAD mice impacted plaque morphology and/or neuronal dystrophy. While plaques in (legend continued on next page)
untreated Trem2 -/-5XFAD mice had a lower density than those in 5XFAD mice as measured by methoxy-X04 staining intensity, the density of plaques in cyclocreatine-treated Trem2 -/-5XFAD mice resembled that of plaques in 5XFAD mice ( Figure 7E ), although plaque shape complexity was not significantly altered ( Figure S5F ). Despite reducing plaque density, cyclocreatine did not moderate plaque accumulation or the engulfment of plaque particulates by microglia, at least at this time point ( Figures  S5G-S5I ). As APP is known to accumulate as distinct rounded particles in dystrophic neurites, we used APP deposition around plaques to assess neurite dystrophy (Masliah et al., 1996; Wang et al., 2016; Yuan et al., 2016) . Cyclocreatine treatment of (F and G) Mitochondrial mass of WT and Trem2 -/-BMDM assessed by Mito Tracker Green incorporation (F) and by the ratio of mitochondrial-to nuclear DNA (G).
Error bar represents mean ± SEM. *p < 0.05, **p < 0.01, or ****p < 0.001 by one-way ANOVA with Holm-Sidak's multiple comparisons test (C) or Student's t test (F and G). Data are representative of at least 3 independent experiments. See also Figure S4 . 
Trem2
-/-5XFAD mice significantly reduced plaque-associated neurite dystrophy compared to untreated Trem2 -/-5XFAD mice to levels observed in 5XFAD mice ( Figures 7F and 7G ). Taken together, these data indicate that cyclocreatine administration improves microglial metabolism and the protective response to Ab plaques in TREM2-deficient 5XFAD mice.
DISCUSSION
Increasing evidence supports the hypothesis that the microglial response to AD lesions controls disease progression (Gold and El Khoury, 2015; Hong et al., 2016 Error bar represents mean ± SEM. *p < 0.05, ***p < 0.005, and ****p < 0.001 by one-way ANOVA with Holm-Sidak's multiple comparisons test (B and D-F) results pooled from 2 independent experiments representing a total of 5-8 male and female mice per treatment group. Arrowheads indicate multilamellar and multivesicular structures (A) or LC3 + vesicles (C).
See also Figure S5 . (Freeman and Ting, 2016; Heneka et al., 2013 Heneka et al., , 2015 . To sustain cytokine secretion, these receptors induce a striking metabolic reprogramming, which consists of a switch from fatty acid metabolism and oxidative phosphorylation to glycolysis (O'Neill and Pearce, 2016). In our study, TREM2 emerges as an innate immune receptor that impacts microglia metabolism in AD through a distinct mechanism, which consists of basic activation of mTOR signaling that supports long-term cell trophism, survival, growth, and proliferation, rather than drastic metabolic reprogramming. This function of TREM2 is reminiscent of the tonic function of the B cell antigen receptor in mature B cells, which delivers survival signals through PI3-K (Werner et al., 2010) . Likewise, cell membrane phospholipids and lipoprotein particles may continuously engage TREM2, inducing tonic mTOR signaling through upstream activators, such as PI3-K, PDK1, and Akt, which are recruited by the TREM2-associated signaling subunits DAP12 and DAP10 (Ford and McVicar, 2009; Peng et al., 2010) . This concept provides a unifying mechanism to explain the reported broad and long-term impact of TREM2 on diverse microglial functions, such as survival, proliferation, clustering around plaques, as well as phagocytosis of apoptotic cells and myelin debris (Jay et al., 2017; Neumann and Takahashi, 2007; Wang et al., 2015; Yeh et al., 2016; Yuan et al., 2016) . We found that the defective mTOR signaling in TREM2-deficient microglia is associated with a compensatory increase of autophagy in vitro and in vivo in AD. Reduced glycolysis and autophagy are known to attenuate inflammation (Netea-Maier et al., 2016) and, indeed, microglia from 5XFAD mice lacking TREM2 weakly express inflammatory mediators in comparison to microglia from 5XFAD mice (Wang et al., 2015) . Moreover, autophagy may also enhance microglial clearance of Ab (Cho et al., 2014; Lucin et al., 2013; Shibuya et al., 2014) , as it does in neurons (Hara et al., 2006; Komatsu et al., 2006; Yang et al., 2011) . However, a long-term defect in mTOR activation results in global microglial dysfunction, reduced cell viability, and proliferation, as demonstrated by increased caspase-3 activation in microglia and by the previously reported increase in dying microglia around plaques in Trem2 -/-5XFAD mice (Wang et al., 2015) . Thus, while increased autophagy may be beneficial in reducing inflammation and Ab load in the short-term, a defect in mTOR signaling is detrimental and severely impairs microglia fitness and capacity to respond to Ab accumulation in the long-term.
TREM2-deficient microglia have been thought to improperly remain in a homeostatic state during neurodegenerative disease rather than responding appropriately to pathology, a paradigm that has been supported by transcriptomic analysis of these cells. However, for the first time, we demonstrate that on a biochemical and ultrastructural level, TREM2-deficient microglia adopt a severely divergent cellular state that does not reflect homeostasis during neurodegeneration, with a dramatic loss of mTOR signaling and robust induction of autophagy. These results suggest that TREM2-deficient microglia are not simply ignoring plaque pathology, but rather that they are being actively driven into a stressed state that is normally compensated by TREM2-dependent survival signals. An important implication of this finding is that microglia in a neurodegenerative environment probably receive not only positive activating signals but also negative cytotoxic signals. Thus, it may not be microglial activation per se that is required to protect against neurodegeneration, but rather avoidance of a dysfunctional, low-energy state induced by the disease. Based on our findings, previous reports of impaired microglial activation in a variety of settings may be due to either impaired recognition of activating signals or to impaired resistance to cytotoxic signals-two possibilities that can be distinguished by the strength of mTOR signaling. Counteracting such dysfunction by metabolic compensation may also represent a fundamentally distinct therapeutic approach.
Along these lines, our study shows that the defect in mTORmediated metabolic activation in TREM2-deficient cells can be corrected in vitro through the creatine kinase pathway or by triggering the Dectin-1 pathway, which transmits intracellular signals similar to those of TREM2. Based on these results, we adopted a therapeutic strategy based on the use of cyclocreatine, an analog of creatine that crosses membranes, enters the brain (Woznicki and Walker, 1979) , can be phosphorylated and dephosphorylated by creatine kinases (McLaughlin et al., 1972) , and can generate a supply of ATP . Remarkably, we found that administration of dietary cyclocreatine throughout the progression of Ab accumulation improves microglia viability, numbers, and clustering around Ab plaques. As a result, plaques are denser and, most importantly, plaqueassociated neurite dystrophy is greatly reduced. Although cyclocreatine treatment was not sufficient to reduce the overall Ab plaque accumulation, this may depend on time point chosen for analysis and/or cyclocreatine dosage and duration of treatment. While the creatine kinase pathway has been previously recognized to play an important role in the CNS in neurotransmitter release, membrane potential maintenance, Ca homeostasis, and ion gradient restoration (Snow and Murphy, 2001; Wyss and Kaddurah-Daouk, 2000) , our results indicate that this system may also be exploited for sustaining microglial metabolism. It should be noted that in certain settings cyclocreatine can inhibit creatine kinase and can also have systemic effects such as alteration in pancreatic hormones and glucose metabolism (Ara et al., 1998; Kuiper et al., 2008) . Thus, it must be emphasized that our findings provide proof of principal studies and the use of cyclocreatine as a preventative treatment for AD is not advisable. Future studies will be required to precisely define the mechanisms through which cyclocreatine impacts microglial responses to Ab. Additionally, it will be important to determine whether cyclocreatine has any impact on proteolytic shedding of TREM2 from microglia, which results in the release of soluble TREM2 with potential pro-survival functions. Altogether, our study indicates that strategies aimed at sustaining microglial metabolism may be promising for therapeutic intervention in AD and other neurodegenerative diseases linked to TREM2 deficiency and microglial dysfunction in general.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Marco Colonna (mcolonna@wustl.edu). 
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Mice were of mixed sexes. Mice within experiments were age and sex matched. For studies using 5XFAD and Trem2 -/-5XFAD animals all animals were 8 months of age at the time of use. For bone marrow and primary microglia mice were used from 6 weeks of age until 12 weeks of age. Mice used in this study include WT C57BL/6J, 5XFAD, Trem2 -/-, and Trem2 -/-5XFAD animals. All animals were backcrossed until at least > 98% C57BL/6J confirmed by genotype wide microsatellite typing. Mice were housed under specific pathogen free conditions. Mice from different genotypes were cohoused. Mice did not undergo any procedures prior to their stated use. For cyclocreatine treatment mixed litters of sex matched mice were randomly assigned to experimental groups. All studies performed on mice were done in accordance with the Institutional Animal Care and Use Committee at Washington University in St. Louis approved all protocols used in this study.
Human post-mortem samples Characteristics of donors of human post-mortem brain tissue at the time of collection is indicated in Table S1 . 
Cell lines and primary cells
Bone marrow derived macrophages and microglia were prepared from sex and age matched mice. To prepare bone marrow-derived macrophages, femurs and tibias were removed and flushed with PBS. Cells were counted and plated at 2.5 3 10 6 cells/100 mm petri dish in RPMI supplemented with Glutamax, penicillin/streptomycin, non-essential amino acids, pyruvate, and 10% heat inactivated fetal bovine serum (complete RPMI) and 10% L-cell conditioned medium (LCCM). Cells were cultured for 4-5 days before use. Microglia were prepared as previously described (Wang et al., 2015) . Briefly, brains were dissociated by using a Neural Tissue Dissociation Kit (T) . Cells suspensions were labeled with anti-mouse CD45 magnetic beads and isolated on LS columns (Miltenyi Biotic). Cells were plated onto poly-L-lysine coated polystyrene plates in complete RPMI supplemented with 20% LCCM and 10 ng/ml human TGF-b. Media was changed on day 3 post plating and cells were used 5-7 days post plating.
TREM2 reporter cells were maintained in 10% FBS in RPMI 1640 supplemented with sodium pyruvate, GlutaMAX, and penicillin/ streptomycin. TREM2 reporter cells were based on the 2B4 NFAT-GFP cells developed by Arase et al. (Arase et al., 2002) . The sex of the mouse from which 2B4 T cell hybridoma cells were derived has not been reported (Arase et al., 2002; Hedrick et al., 1982) .
METHOD DETAILS Mice
The generation of Trem2 -/-and Trem2 -/-5XFAD mice has been described previously (Oakley et al., 2006; Turnbull et al., 2006; Network analysis Network analysis was performed as previously described utilizing Shiny GAM (https://artyomovlab.wustl.edu/shiny/gam/) (Sergushichev et al., 2016; Vincent et al., 2015) . We considered a network of chemical mappings between carbon atoms in substrates and products for all annotated reactions in KEGG database using RPAIRs entries. The scores for nodes and edges were assigned according to log(p value), such that highly significant gene or metabolite signals had positive scores and not significant had negative scores. Using an exact solver (https://github.com/ctlab/sgmwcs-solver) we found a module with a maximal weight, with counting positive scores maximum once for a measured entity (a mass-spectrometry peak or a gene). For clarity, addition edges between nodes in the module were added if the corresponding gene was highly expressed (was in a top 3000 expressed genes).
qRT-PCR Total RNA was isolated with TRIzol Reagent (Invitrogen) and single-strand cDNA was synthesized with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Genomic DNA was extracted using the QIAamp DNA micro kit (QIAGEN) to determine mtDNA/nDNA ratios. Real-time PCR was performed using SYBR Green real-time PCR master mix (Thermo-Fisher) and LightCycler 96 detection system (Roche). mtDNA primers were to cytochrome c oxidase subunit 1 and nDNA primers were to NADH:ubiquinone oxidoreductase core subunit V1.
Metabolism assays
For real-time analysis of extracellular acidification rates (ECAR) macrophages were analyzed using an XF96 Extracellular Flux Analyzer (Agilent Technologies). Cells were incubated overnight in complete RPMI in the indicated concentration of LCCM with or without cyclocreatine (10 mM). Measurements were taken under basal conditions and following the sequential addition of 1 mM oligomycin and 1.5 mM fluoro-carbonyl cyanide phenylhydrazone (FCCP) (purchased from Sigma-Aldrich).
Transmission electron microscopy For ultrastructural analyses, cells were fixed in 2% paraformaldehyde/2.5% glutaraldehyde in 100 mM sodium cacodylate buffer, pH 7.2 for 1 hr at RT (Polysciences Inc., Warrington, PA). Samples were washed in sodium cacodylate buffer and postfixed in 1% osmium tetroxide for 1 hr (Polysciences Inc.). Samples were then rinsed extensively in deionized water prior to en bloc staining with 1% aqueous uranyl acetate for 1 hr (Ted Pella Inc., Redding, CA). Following several rinses in dH 2 0, samples were dehydrated in a graded series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA). For quantitation of multivesicular/multilamellar structures, 30 cells that were cross-sectioned through the nucleus (indicating cross-section through the middle of cell) were randomly chosen, and images of each cell were taken at 6,000X and 20,000X magnification. The cross-sectional area of each of the multivesicular structures were determined using ImageJ 1.38 g (National Institutes of Health, USA, customized for AMT images). Data is expressed as the 1) total number of a multivesicular/multilammelar structures per cross-sectional area of cytosol and 2) the total cross-sectional area of multivesicular/multilamellar structures per area of cytosol.
Preparation of brain samples and confocal microscopy Confocal microscopy analysis was preformed as previously described (Wang et al., 2015) . Briefly, mice were anesthetized with ketamine/xylazine and perfused with ice-cold PBS containing 1 U/ml of heparin. Brains were fixed in 4% PFA overnight at 4 C rinsed in PBS and incubated overnight at 4 C in 30% sucrose before freezing in a 2:1 mixture of 30% sucrose and optimal cutting temperature compound. Serial 40 mm coronal sections were cut on a cryo-sliding microtome. Floating sections from 1.1 mm Bregma to 0.8 mm Bregma for cortical imaging or slides with fixed human sections were stained with Iba-1 (Waco Chemicals Cat. Number 019-19741) overnight at 4 C followed by staining with anti-rabbit IgG DyLight 549 (Vector Laboratories Cat. Number DI-1549) and methoxy-X04 (Tocris Cat. Number 4920) for 1 hr at RT. Finally, sections were stained for with anti-LC3 Alexa 488 ± anti-cleaved caspase 3 (Cell Signaling Technologies Cat. Number 13082 and 9602). Images were collected using a Nikon A1Rsi+ confocal microscope. Images were then processed with Imaris 7.7 (Bitplane).
Microglia clustering analysis
Positions of microglia and positions and volumes of plaques within z stacks were derived from analysis in Imaris, and microglia-plaque association was determined using automated scripts in MATLAB. Briefly, each plaque in the z stack was modeled as an idealized sphere with the same volume and center of mass. Microglia density within 15 mm of the plaque surface was determined by isolating the voxels of the image that fall within 15 mm of the edge of the idealized plaque. The number of microglia contained in these voxels was divided by the total volume of those voxels to obtain density for a single plaque. Densities of all plaques in a z stack were averaged together, and the resulting values were averaged together for all z stacks corresponding to a single animal.
Reporter cell assay
The 2B4 T cell hybridoma cell line was retrovirally transduced with an NFAT-GFP reporter construct, and TREM2 reporter cells were generated by a second retroviral transduction with a TREM2 overexpression construct and selected by puromycin resistance, as previously described (Wang et al., 2015) . Cells were cultured routinely in complete media (10% FBS in RPMI-1640 supplemented with sodium pyruvate, GlutaMAX, and penicillin/streptomycin). For serum starvation, cells were plated at a density of 25,000 cells/well in a 96-well plate in either complete media or RPMI-1640 in the presence of 20% anti-TREM2 hybridoma supernatant (clone M178, generated in house) or 20% isotype control hybridoma supernatant (Wang et al., 2015) . After 16 hr, the percent of GFP+ cells among live cells was measured by flow cytometry.
Quantification of methoxy-X04 coverage
To measure total plaque area, brain sections were stained with methoxy X04. Images were collected using a Nikon Eclipse 80i microscope. For quantitative analysis, images were converted to 8-bit greyscale and stitched using the ''Stitching'' plugin in ImageJ. Cortex ($1.1 mm Bregma to 0.8 mm Bregma) and hippocampus ($-1.7 Bregma to -2.4 Bregma) were determined by manual selection. The threshold of selected images were set at 1.5x mean intensity of the selected area to highlight plaques and analyzed using the ''Measure'' function in ImageJ to calculate the percent area covered. Identified objects after thresholding were individually inspected to confirm the object as a plaque or not. Two brain sections per mouse were used for quantification. The average of two sections was used to represent a plaque load for each mouse.
Plaque morphology analysis
Methoxy-X04-stained sections were imaged by confocal microscopy using a 60X objective and 1.5X digital zoom in the cortex at $1.1 mm Bregma to 0.8 mm Bregma. Z images were taken at 1.2 mm intervals. 20-30 mm z stacks were z-projected by maximum intensity projection and individual plaques were selected in ImageJ. Each individual plaque was traced using a combination of thresholds and edge detection and smoothened using image erosion. The average intensity was determined by averaging values of pixels within the plaque trace. The shape index was calculated as 4p*(perimeter pixels) 2 /(all pixels).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data in figures are presented as mean ± SEM. Unless otherwise stated statistical analysis was performed using Prism (GraphPad). Quantification of confocal microscopy, immunoblots, and electron microscopy images were performed using Imaris, ImageJ, MATLAB, and FIJI. Differential metabolite expression was analyzed using limma. Pathway analysis of microarray data was performed using IPA software. RNaseq analysis was performed by using Second read (read-mate) for sample demultiplexing. Reads were aligned using STAR aligner and quantified using quant3p scirpt. RefSeq genome annotation was used and DESeq2 was used for differential gene expression analysis. Combined RNaseq and metabolite network analysis was performed utilizing Shiny GAM. Statistical analysis to compare the mean values for multiple groups was performed using Prism by one-way ANOVA with Holm-Sidak's multiple comparisons test. Comparison of two groups was performed in Prism using a two-tailed unpaired t test (Mann Whitney). Values were accepted as significant if p % 0.05. Intragroup variation compared between groups was similar in all experiments.
DATA AND SOFTWARE AVAILABILITY
Microarray data has been deposited at GEO: GSE65067. RNA-seq data has been deposited at GEO: GSE98563. 
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